

09997.0087US01

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : FRANZ Michel  
Appl. No. : 10/789,174  
Filed : February 26, 2004  
For : STABILIZED  
PHARMACEUTICAL  
COMPOSITION COMPRISING  
AN EXTENDED RELEASE NON-  
STEROIDAL ANTI-INFLAMMATORY  
AGENT AND AN IMMEDIATE RELEASE  
PROSTAGLANDIN  
Examiner : SILVERMAN, ERIC  
Group Art Unit : 1619

DECLARATION UNDER 37 C.F.R § 1.132

**Mail Stop Amendment**

Commissioner for Patents  
P.O Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

1. This Declaration is being submitted to demonstrate that claimed invention unexpectedly provides a stability of pharmaceutical composition comprising an extended release non steroidal anti-inflammatory agent and an immediate release prostaglandin.
2. I am an inventor on the above- identified patent application and am familiar with the specification and prosecution history.
3. I have extensive experience in the field of the claimed invention as indicated in the attached Curriculum Vitae provided herewith as Exhibit A.

Appl. No. : 10/789,174  
Filed : February 26, 2004

4. I have conducted Hydroxyl-Propyl-Methyl-cellulose (HPMC) a stability study during a period of 6 months. Capsules made of gelatine and made of hydroxyl-Propyl-Methyl-cellulose (HPMC) (containing extended release non-steroidal anti-inflammatory agents and an immediate release prostaglandin) were compared. The protocol of this study and the results of this study is presented in the enclosed Exhibit B.
5. This comparative data shows that a capsule made of Hydroxyl-Propyl-Methyl-cellulose present unexpectedly an increase stability compared to gelatine.
6. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issuing therefrom.

Dated: October 26<sup>th</sup> 2006

By:   
Michel Franz

**Michel FRANZ**

avenue du Haut-Champ,52

B-1082 Brussels

michel.franz@skynet.be

Tel: 32(0)2 4654434 Cell Phone: 32(0)2 497 421363 Fax: 32(0)2 4694855

**Profile**

When graduated as a Pharmacist at Liège University (Belgium), I had two major areas of interest: Pharmacognosy and Pharmaceutical Technology.

I started with 2 years in Congo/Zaire at the University of Kinshasa ( instead of military service) and came back in Belgium to begin a career in the Pharmaceutical Industry.

My first responsibilities were in manufacturing but I managed to move progressively to Pharmaceutical Development responsibilities.

I had the opportunity to work for several important pharmaceutical companies including Baxter, Laboratoires Thissen, UCB Pharma, Monsanto/ Searle, Lilly and Janssen Research Foundation, accumulating a broad experience in the early pharmaceutical development activities as well as the late stage technology transfer.

In parallel to my professional career, I was able to develop an interesting network in Belgium and abroad (Universities, Health and Business Authorities, Industrial Pharmacists, Excipients and Active Ingredients Suppliers, Machine Manufacturers) .

**Personal informations**

- Date of birth: 2 september 1945
- Nationality: belgian
- Education :
  - University of Liège (1963-1968) : Pharmacist , Magna Cum Laude
  - University of Brussels(1981-1982) : Solvay Business School Certificate
- Languages:
  - French , mother language
  - English , good spoken and written
  - Dutch: good spoken

**Miscellaneous**

- Elected on the list of Industrial Pharmacists of the Belgian Health Ministry, n°598 (Qualified Person to release pharmaceutical products in the European Community)
- Visiting Professor and co-founder of the post -graduate teaching in Industrial Pharmacy organised by the 3 French speaking Universities in Belgium.
- Past Chairman and current member of the board of UPIP VAPI (Belgian Industrial Pharmacists Professional Association) and past national representative to the European Federation of sister associations.
- Active member in several professional and scientific other organisations
- Author or co-author of several publications and patents
- Good knowledge of the retail pharmacy and hospital pharmacy activities in Europe and Africa

### Experience and Achievements

From beginning of 1999- today- **FRANPHARMA** sprl

- **Consultant** in Pharmaceutical Product Development
- Missions in Belgium, France, The Netherlands, North Africa and the US.

1996 to January 1999- **Janssen Research Foundation** (Beerse)

- *Senior Project Manager*
- I had to coordinate pharmaceutical product development activities on projects being worked out intra the company or in collaboration with Drug Delivery Companies

1993-1996- **Lilly Development Centre** (Mont-Saint-Guibert)

- *Scientific Advisor*
- The function included the following responsibilities:  
Advice to the Pharmaceutical Development activities  
Contacts to identify opportunities in the field of Drug Delivery Systems  
Improvement of the network with Universities and other official bodies in Belgium and in Europe

1978-1993- **Continental Pharma / Monsanto/ Searle** (Louvain-la-Neuve)

- Management positions in (bio)pharmaceutical development, R&D  
Last: *Senior Director*, European Pharmaceutical Development
- The function included the following responsibilities (analytical & technological):  
Pre-formulation, formulation for New Chemical Entities  
Design of new formulations for existing products  
Manufacturing and Quality Control of dosage forms used during clinical trials  
Packaging of clinical supplies for international studies (shipment to 40 countries)  
Technology Transfert to manufacturing sites in France, UK, Puerto Rico, Germany  
Participation to the selection of manufacturing equipment and Plant design for Manufacturing and Control  
Preparation of the CMC section of regulatory affairs documents for worldwide applications
- The biggest project we finalised is Arthrotec, a patented core tablet (US 5,015,481) with cumulated sales well over 1 billion \$!

1974-1978- **UCB Pharma** (Brussels and Braine-l'Alleud)

- *Pharmaceutical Technology Manager*
- I have (re)formulated several key products, including Nootropil tablets
- The job gave me the opportunity to work in both Manufacturing & Control and R & D environments.

1972-1974- **Laboratoires Thissen** (Therabel Group) Uccle

- *Manufacturing Supervisor*
- In a short period of time I was able to gather a good experience as the company is working as a contract lab.  
The diversified nature of the products was giving me a prime chance to solve formulation issues.

1971-1973- **Baxter-Travenol** (Lessines)

- *Quality Control Supervisor*
- I was exposed early in my career to the concept of the GMPs, in a state of the art plant built to produce Large Volume Parenterals and other hospital products.

1969-1971- **University of Kinshasa** (Zaire)

- *Lecturer at the School of Pharmacy*
- In addition to teaching I was doing research on endemic plants (Strychnos and Dioscoreas).

A stability study has been performed during a period of 6 months. Capsules made of gelatine of hydroxypropylcellulose (HPMC) containing Extended Release Diclofenac Sodium pellets and one Immediate Release Misoprostol mini-tablet were compared.

The attention was focused on the stability of Misoprostol as it is a very sensitive compound. The analytical methodology to assay Misoprostol and the impurities was based on the monograph recently published in the European Pharmacopeia (monograph 1731, January 2006).

The moisture of the Misoprostol mini-tablets was designed to be high to accelerate the degradation of Misoprostol and to facilitate the evidence of the possible difference between the 2 types of capsules. The mini-tablets moisture results were : 7,44% in the gelatine capsules and at 7.98% in the HPMC capsules.

Both types of capsules were packaged in aluminium-aluminium blisters which are offering an excellent protection against atmospheric agents during the storage.

We report the results obtained on packaged capsules stored at 30°C/65% Relative Humidity and 40°C/75% Relative Humidity.

The comparison of the data indicates clearly that the use of HPMC capsules offers a clear advantage over the gelatine capsules for the stability of the prostaglandin.

Condition : + 30°C/65% RH

Timepoint (months)	Misoprostol Content (mg)	Misoprostol Content (% of label claim)	Total Epimers	Misoprostol A	Misoprostol B	Total impurities
Gelules gelatine						
0	0,193	96,7	0,68	0,14	nd	0,82
1	0,197	98,3	0,93	0,46	0,04	1,45
3	0,191	95,7	1,19	0,87	0,15	2,21
6	0,188	94	1,85	1,90	0,62	4,37
Gelules HPMC						
0	0,191	95,5	0,77	0,12	nd	0,89
1	0,197	98,6	1,04	0,39	0,01	1,44
3	0,195	97,4	1,34	0,66	0,03	2,03
6	0,191	95,7	1,01	1,20	0,08	2,29

Condition : + 40°C/75% RH

Timepoint (months)	Misoprostol Content (mg)	Misoprostol Content (% of label claim)	Total Epimers	Misoprostol A	Misoprostol B	Total impurities
Gelules gelatine						
0	0,193	96,7	0,68	0,14	nd	0,82
1	0,192	95,8	1,63	2,12	0,66	4,41
3	0,175	87,6	2,43	4,07	2,37	8,87
6	0,151	75,5	4,33	6,94	6,03	17,30
Gelules HPMC						
0	0,191	95,5	0,77	0,12	nd	0,89
1	0,197	98,7	1,18	1,63	0,09	2,90
3	0,186	93,1	1,69	3,53	0,23	5,45
6	0,174	87,1	1,87	7,66	0,62	10,14

Impurities are expressed in % of the theoretical amount of Misoprostol.

G:\isabelle\p.FRAN.01EPTABLEAUX